Latest journalAll journals
Welcome to the latest issue of EMJ Rheumatology! We are pleased to share with you a collection of the latest rheumatology insights, peer-reviewed research, and exclusive interviews with experts in the field, alongside our review of the European League Against Rheumatism (EULAR) Congress 2021 with research updates and news from the virtual event.
Latest articlesAll articles
Subscribe to EMJ today to have the next EMJ #Rheumatology eJournal sent straight to you! ow.ly/w5XX30q3OFJ https://t.co/Hya4zIIBgF
Posted 19 September
We sit down with Meryvn Singer, Professor of Intensive Care Medicine, UCL, to discuss the role of intensive care in… twitter.com/i/web/status/1…
Posted 18 September
Why not take a look back at #EULAR2021. The annual congress, brought together students, researchers, clinicians, an… twitter.com/i/web/status/1…
Posted 17 September
The table shows the assessments of chronic inflammatory diseases. Learn more by following the link:… twitter.com/i/web/status/1…
Posted 15 September
This review provides a summary of presentations from the ACR Convergence 2020 meeting and collectively describes… twitter.com/i/web/status/1…
Posted 14 September
Latest abstractsAll abstracts
Differences in Low-Density Lipoprotein Particle Composition and Oxidation May Underlie the Paradoxical Association of Low Levels with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
In fact, patients with RA in the lowest low-density lipoprotein (LDL) group (<70 mg/dL) may experience an unexpectedly high CVD risk.2 The authors explored whether patients with LDL 130 mg/dL), as a reason for this risk.
Association Between Environmental Air Pollution and Rheumatoid Arthritis Flares
Environmental air pollution has been linked to the pathogenesis of rheumatoid arthritis (RA).1 Nevertheless, there is no evidence linking higher concentrations of air pollutants with the risk of RA reactivations.
RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis